5-Minute Pharma Daily(feeds.transistor.fm)
Ipsen makes up to $1.75B blood cancer bet with Kartos buyoutViridian debuts on market with FDA greenlight for thyroid eye disease drugBridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit4 ovarian cancer candidates to watch: GSK, Allarity and moreCapricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapyBIO 2026: Making biotech IPOs great again and the forgotten pharma antitrust reviewThe hidden cost of FDA unpredictability
BioPharma Dive - Latest News(biopharmadive.com)
10 clinical trials to watch in the second half of 2026FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences servicesAt BIO, tension over China biotech deal regulation loomsAlkermes’ incoming CEO has a plan to outplay Lilly and TakedaOn second try, Acadia drug gets nod from European regulatorsRemix to go public in reverse merger with once high-flying Passage BioAntares gets $105M from Novartis for new cancer drugs
Merck's $11.3B Bio-Techne Acquisition | Pharma and Biotech DailyEli Lilly's $1.9B Abbisko Partnership Boosts Cancer R&D | Pharma and Biotech DailyCarsgen's $2T Satricabtagene Approval Milestone | Pharma and Biotech DailyCarsgen's CAR-T Breakthrough in China for Solid Tumors | Pharma and Biotech DailyFDA Approves Alzheimer's Drug Amid Debate | Pharma and Biotech DailyFDA Approves Utebzi, Biogen Acquires Raythera for $1B | Pharma and Biotech DailyEli Lilly's $65B M&A Surge & FDA's Drug Import Approval | Pharma and Biotech Daily
UAE launches first genomics-driven clinical trial to prevent Alzheimer’s diseaseViridian wins FDA approval for Lumvoa for thyroid eye diseaseForce for functionalityDefending batch integrityRacura treats first patient in phase 1 HARNESS‑1 lung cancer trialNICE recommends MSD’s pembrolizumab for locally advanced cervical cancerLundbeck to present new Vyepti and bocunebart data at EAN 2026
Opinion: Supreme Court ruling on Roundup points to a confusing difference between the law and scienceBIO 2026: AI, federal policy impacts, and general vibesSTAT+: Up and down the ladder: The latest comings and goings988’s LGBTQ+ hotline to relaunch this year. But the group that helped start it might be excludedSTAT+: Embryo editing advances reignite ethical debatesSTAT+: Pharmalittle: We’re reading about a bill to overhaul the 340B program, a new FDA commissioner candidate, and moreSTAT+: European antitrust regulators probe Sanofi for allegedly disparaging a rival flu vaccine